Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study

References

• Rowinsky, E K.; Donehower, R C. Paclitaxel (taxol). N. Engl. J. Med. 1995, 332, 1004–1014. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Younes, A.; Sarris, A.; Melnyk, A.; Romaguera, J.; McLaughlin, P.; Swan, F.; Rodriguez, M A.; Hagemeister, F.; Moore, D.; North, L.; Smith, T L.; Cabanillas, F. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 1995, 13, 583–587. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wilson, W H.; Chabner, B A.; Bryant, G.; Bates, S.; Fojo, A.; Regis, J.; Jaffe, E S.; Steinberg, S M.; Goldspiel, B R.; Cheson, B D.; Wittes, R E. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J. Clin. Oncol. 1995, 13, 381–386. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Younes, A.; Ayoub, J P.; Hagemeister, F B.; McLaughlin, P.; Sarris, A.; Rodriguez, M A.; Swan, F., Jr.; Romaguera, J E.; Martin, J.; Cabanillas, F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J. Clin. Oncol. 1996, 14, 543–548. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Younes, A.; Ayoub, J P.; Sarris, A.; Hagemeister, F.; North, L.; Pate, O.; McLaughlin, P.; Rodriguez, M A.; Romaguera, J.; Kurzrock, R.; Preti, A.; Bachier, C.; Smith, T.; Cabanillas, F. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br. J. Haematol. 1997, 96, 328–332. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Younes, A. Paclitaxel for the treatment of lymphoma. J. Clin. Oncol. 1998, 16, 2289–2290. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Press, O W.; LeBlanc, M.; O'Rourke, T J.; Gagnet, S.; Chapman, R A.; Balcerzak, S P.; Fisher, R I. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J. Clin. Oncol. 1998, 16, 574–578. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Goss, P.; Stewart, A K.; Couture, F.; Klasa, R.; Gluck, S.; Kaizer, L.; Burkes, R.; Charpentier, D.; Palmer, M.; Tye, L.; Dulude, H. Combined results of two phase II studies of taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk. Lymphoma 1999, 34, 295–304. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cheson, B D.; Horning, S J.; Coiffier, B.; Shipp, M A.; Fisher, R I.; Connors, J M.; Lister, T A.; Vose, J.; Grillo-Lopez, A.; Hagenbeek, A.; Cabanillas, F.; Klippensten, D.; Hiddemann, W.; Castellino, R.; Harris, N L.; Armitage, J O.; Carter, W.; Hoppe, R.; Canellos, G P. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999, 17, 1244–1253. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Fennelly, D.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; McKenzie, M.; O'Connor, C.; Tong, W.; Norton, L.; Spriggs, D. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 1997, 15, 187–192. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Akerley, W.; Glantz, M.; Choy, H.; Rege, V.; Sambandam, S.; Joseph, P.; Yee, L.; Rodrigues, B.; Wingate, P.; Leone, L. Phase I trial of weekly paclitaxel in advanced lung cancer. J. Clin. Oncol. 1998, 16, 153–158. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Oettle, H.; Arnold, D.; Esser, M.; Huhn, D.; Riess, H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000, 11, 635–638. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Trivedi, C.; Redman, B.; Flaherty, L E.; Kucuk, O.; Du, W.; Heilbrun, L K.; Hussain, M. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000, 89, 431–436. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seidman, A D.; Hudis, C A.; Albanel, J.; Tong, W.; Tepler, I.; Currie, V.; Moynahan, M E.; Theodoulou, M.; Gollub, M.; Baselga, J.; Norton, L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 1998, 16, 3353–3361. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vaughn, D J.; Broome, C M.; Hussain, M.; Gutheil, J C.; Markowitz, A B. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J. Clin. Oncol. 2002, 20, 937–940. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lopes, N M.; Adams, E G.; Pitts, T W.; Bhuyan, B K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother. Pharmacol. 1993, 32, 235–242. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Seidman, A D.; Hochhauser, D.; Gollub, M.; Edelman, B.; Yao, T J.; Hudis, C A.; Francis, P.; Fennelly, D.; Gilewski, T A.; Moynahan, M E.; Currie, V.; Baselga, J.; Tong, W.; O'Donaghue, M.; Salvaggio, R.; Auguste, L.; Spriggs, D.; Norton, L. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J. Clin. Oncol. 1996, 14, 1877–1884. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chang, A Y.; Boros, L.; Garrow, G.; Asbury, R. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin. Oncol. 1995, 22, 124–127. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Vahdat, L.; Papadopoulos, K.; Lange, D.; Leuin, S.; Kaufman, E.; Donovan, D.; Frederick, D.; Bagiella, E.; Tiersten, A.; Nichols, G.; Garrett, T.; Savage, D.; Antman, K.; Hesdorffer, C S.; Balmaceda, C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin. Cancer Res. 2001, 7, 1192–1197. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar